Cargando…

Comparison of education group strategies and home visits in type 2 diabetes mellitus: clinical trial

OBJECTIVE: to compare the adherence and empowerment of patients with type 2 diabetes mellitus for self-care practices and glycemic control in group education strategies and home visits. METHOD: Clinical trial with ten randomized clusters, performed with 238 patients with type 2 diabetes mellitus dis...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Santos, Jéssica Caroline, Cortez, Daniel Nogueira, Macedo, Maísa Mara Lopes, Reis, Edna Afonso, Reis, Ilka Afonso, Torres, Heloísa Carvalho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Escola de Enfermagem de Ribeirão Preto / Universidade de São Paulo 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738960/
https://www.ncbi.nlm.nih.gov/pubmed/29267547
http://dx.doi.org/10.1590/1518-8345.2315.2979
Descripción
Sumario:OBJECTIVE: to compare the adherence and empowerment of patients with type 2 diabetes mellitus for self-care practices and glycemic control in group education strategies and home visits. METHOD: Clinical trial with ten randomized clusters, performed with 238 patients with type 2 diabetes mellitus distributed in group education, home visit, and control group. Socio-demographic data, glycated hemoglobin and those obtained from the self-care and empowerment questionnaires were collected. Statistical analysis was performed separately by educational strategy. RESULTS: the mean age of the patients was 57.8 years old (SD = 9.4 years old), with a predominantly female participation (66.4%). Both strategies presented similar results regarding adherence to self-care practices and patient empowerment. There was also a reduction in glycated hemoglobin levels; however, only in the education group, the difference presented statistical significance (p <0.001). CONCLUSION: the strategies were effective; however, group education presented better glycemic control results in relation to the home visit. International registry: NCT02132338 and national: RBR-92j38t in the clinical trials registry.